KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Revenue (2020 - 2025)

Historic Revenue for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $5.2 million.

  • Recursion Pharmaceuticals' Revenue fell 8015.87% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year decrease of 3297.59%. This contributed to the annual value of $58.8 million for FY2024, which is 3200.0% up from last year.
  • Recursion Pharmaceuticals' Revenue amounted to $5.2 million in Q3 2025, which was down 8015.87% from $19.2 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Revenue peaked at $26.1 million during Q3 2024, and registered a low of $2.5 million during Q4 2021.
  • Moreover, its 5-year median value for Revenue was $10.9 million (2023), whereas its average is $10.1 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Revenue surged by 417000.0% in 2021, and later plummeted by 8015.87% in 2025.
  • Recursion Pharmaceuticals' Revenue (Quarter) stood at $2.5 million in 2021, then surged by 439.91% to $13.7 million in 2022, then decreased by 20.36% to $10.9 million in 2023, then crashed by 58.26% to $4.5 million in 2024, then increased by 13.84% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $19.2 million for Q2 2025, and $14.7 million during Q1 2025.